Literature DB >> 31318999

Astragaloside IV attenuates inflammatory injury and promotes odontoblastic differentiation in lipopolysaccharide-stimulated MDPC-23 cells and rat pulpitis.

Qun Ding1, Jinyu Gao2, Jing Zheng1, An Wang1, Shuanrang Jing1.   

Abstract

BACKGROUND: Astragaloside IV (AS-IV), a natural herbal compound from Astragalus membranaceus, has inhibitory effects on receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclastogenesis, and RANKL signal helps to regulate odontoblast differentiation. However, whether and how AS-IV affects odontoblastic differentiation remains unclear.
METHODS: Lipopolysaccharide (LPS)-stimulated MDPC-23 cells and rat pulpitis were treated with AS-IV, cell viability, and LDH leakage was analyzed by CCK-8 assay and LDH Leakage assay. The production of TNF-α and IL-6 was determined by ELISA and qRT-PCR assay. The expression of alkaline phosphatase (ALP) was detected using an ALP assay kit, and the expression of dentin sialophos-phoprotein (DSPP), dentin matrix protein-1 (DMP1), basic fibroblast growth factor (FGF2), and phosphorylated extracellular signal-regulated kinase (p-ERK) was determined by western blot.
RESULTS: AS-IV dose dependently increased in cell viability and decreased the overproduction of TNF-α and IL-6 in LPS-stimulated MDPC-23 cells. AS-IV also counteracted LPS-induced downregulation of ALP, DSPP, and DMP1 in MDPC-23 cells. Furthermore, AS-IV significantly decreased the expression of FGF2 and p-ERK in LPS-stimulated MDPC-23 cells. More important, the addition of FGF2 partly neutralized AS-IV-mediated inhibition of FGF2/ERK signaling, abolished AS-IV-induced reduction of TNF-α and IL-6, and counteracted AS-IV-induced upregulation of DSPP and DMP-1 in these cells. Meanwhile, AS-IV inhibited the excessive production of TNF-α and IL-6, suppressed the downregulation of DSPP and DMP1, and disturbed the up-regulation of FGF2 and p-ERK in the pulp tissues of rat pulpitis model.
CONCLUSIONS: AS-IV exerted anti-inflammatory and pro-differentiation effects in LPS-stimulated MDPC-23 cells and rat pulpitis via inhibiting the FGF2/ERK signaling pathway.
© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Astragaloside IV; fibroblast growth factor 2; inflammation; odontoblastic differentiation

Year:  2019        PMID: 31318999     DOI: 10.1111/jop.12926

Source DB:  PubMed          Journal:  J Oral Pathol Med        ISSN: 0904-2512            Impact factor:   4.253


  3 in total

1.  Astragaloside IV alleviates placental oxidative stress and inflammation in GDM mice.

Authors:  Ling Zhou; Ruixue Zhang; Shuangyan Yang; Yaguang Zhang; Dandan Shi
Journal:  Endocr Connect       Date:  2020-10       Impact factor: 3.335

2.  Astragaloside IV protects against iron loading-induced abnormal differentiation of bone marrow mesenchymal stem cells (BMSCs).

Authors:  Hui Jin; Jianyang Du; Huan Ren; Guofu Yang; Wenbo Wang; Jianyang Du
Journal:  FEBS Open Bio       Date:  2021-03-17       Impact factor: 2.693

3.  Astragaloside IV protects against ischemia/reperfusion (I/R)-induced kidney injury based on the Keap1-Nrf2/ARE signaling pathway.

Authors:  Yanyan Su; Jiaqi Xu; Siqi Chen; Junxia Feng; Jingchun Li; Zihan Lei; Lingyan Qiao; Yaning Wang; Dewang Zeng
Journal:  Transl Androl Urol       Date:  2022-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.